Brief: NRX Pharmaceuticals And Nephron Pharmaceuticals Agree To Develop Intravenous Ketamine To Treat Suicidal Depression
06/11/2023 11:52
Nov 6 (Reuters) - NRX Pharmaceuticals Inc NRXP.O :
* NRX PHARMACEUTICALS AND NEPHRON PHARMACEUTICALS ANNOUNCE
JOINT
AGREEMENT TO DEVELOP INTRAVENOUS KETAMINE TO TREAT SUICIDAL
DEPRESSION
* NRX PHARMACEUTICALS INC - PARTNERS AIM TO SUBMIT NEW DRUG
APPLICATION BY MARCH 1, 2024
* NRX PHARMACEUTICALS INC - FINISHED DRUG WITH TWO-YEAR
SHELF
STABILITY TARGETED FOR NOVEMBER 2024, PENDING FDA APPROVAL
Source text for Eikon: ID:nPn93S8xVa
Further company coverage: NRXP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on NRX Pharmaceuticals
See all newsBrief: NRx Pharmaceuticals Reschedules Conference Call To Discuss Third Quarter And Year To Date 2024 Financial Results To November 18, 2024
U.S. RESEARCH ROUNDUP-Cintas Corp, Sprouts Farmers market, Voya Financial
U.S. STOCKS ON THE MOVE-Molson Coors, Starbucks, Warner Bros Discovery
U.S. STOCKS ON THE MOVE-Zebra Technologies, Ecolab, American Electric Power
NRX Pharmaceuticals Inc expected to post a loss of 7 cents a share - Earnings Preview